Immune-related Adverse Events Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting immune-related adverse events clinical trials across 6 countries. Studies span Not Applicable, Phase 1, Phase 2. Top locations include Beijing, Beijing Municipality, China, Boston, Massachusetts, United States, Fuzhou, Fujian, China. Updated daily from ClinicalTrials.gov.


Immune-related Adverse Events Trials at a Glance

8 actively recruiting trials for immune-related adverse events are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Not Applicable with 1 trial, with the heaviest enrollment activity in Beijing, Boston, and Fuzhou. Lead sponsors running immune-related adverse events studies include Guohui Li, Hospital Universitario Araba, and Brigham and Women's Hospital.

Browse immune-related adverse events trials by phase

Treatments under study

About Immune-related Adverse Events Clinical Trials

Looking for clinical trials for Immune-related Adverse Events? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune-related Adverse Events trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune-related Adverse Events clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

Immune-related Adverse Events
Peking Union Medical College Hospital500 enrolled1 locationNCT07453342
Recruiting
Not Applicable

Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma

Quality of LifeObjective Response RatePathological Complete Remission+1 more
The Second Hospital of Shandong University25 enrolled1 locationNCT07430579
Recruiting

Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors

Solid TumorImmune-related Adverse EventsImmunotherapy Toxicity
Shantou University Medical College940 enrolled6 locationsNCT07357636
Recruiting

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

Solid TumorsSjogren SyndromeImmune-related Adverse Events+3 more
Hospital Universitario Araba300 enrolled1 locationNCT07249060
Recruiting

Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids

CancerImmune-Mediated HepatitisImmune-related Adverse Events
University Hospital, Basel, Switzerland63 enrolled2 locationsNCT07167251
Recruiting
Phase 1Phase 2

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

MalignancyImmune-related Adverse Events
Brigham and Women's Hospital100 enrolled2 locationsNCT06789601
Recruiting

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

PD-1Immune-related Adverse Events
Guohui Li100 enrolled1 locationNCT04840355
Recruiting

A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

ImmunotherapyImmune-related Adverse EventsPneumonitis, Interstitial
Universitaire Ziekenhuizen KU Leuven60 enrolled1 locationNCT04807127